We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses.
Back in 2024, on May 17, a caller asked about Pfizer Inc., which had struggled post-COVID. Cramer said the turnaround was underway and highlighted the stock’s dividend and pipeline, saying:
“I like Pfizer here. It’s making a big turn — people don’t even seem to be aware of it. I’ve been talking about it every day in the office. I keep saying, ‘Has anyone watched this turn in Pfizer?’ 5.8% yield. I always liked Seagen, which is the old Seattle Genetics — I think Dr. Bourla’s got it right. They have a lot of cash. Yes — Pfizer is a buy.”
Pfizer failed to deliver the turnaround Cramer expected, with shares down 21.06% since his buy recommendation.
A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.
Pfizer Inc. is struggling to reassure investors despite a strong dividend and recent oncology-focused acquisitions. When asked about it again recently, Cramer stated that he remains a believer in the stock. Here’s what he said on May 12:
“You know, look, I think Pfizer, I think it can bottom here. I do believe, I still believe in the Seagen acquisition. I know I seem like, that I’m alone along with Dr. Bourla, but I think that there’s a lot of good stuff that they have, so I would say keep it here.”
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
This article is originally published at Insider Monkey.
